MSMB variation and prostate cancer risk: Clues towards a possible fungal etiology

Prostate

Volumn 74, Issue 6, 2014, Pages 569-578

  Sutcliffe, Siobhan ^a   De Marzo, Angelo M ^b   Sfanos, Karen S ^b   Laurence, Martin ^c  

^a MO   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Shipshaw Labs   (Canada)

Author keywords

fungi; MSMB; prostate cancer; prostate secretory protein 94

Indexed keywords

BETA MICROSEMINOPROTEIN;

ARTICLE; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CYTOSOL; EPITHELIUM CELL; FUNGICIDAL ACTIVITY; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MSMB GENE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOGENESIS;

FUNGI; MSMB; PROSTATE CANCER; PROSTATE SECRETORY PROTEIN 94;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MYCOSES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RISK;

EID: 84897025426     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22778     Document Type: Article

References (94)

1. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC,. Initiative CO-CRUG-E, Australian Prostate Cancer B, Oncology UKGPCSCBAoUSSo, Collaborators UKPS, Consortium P, Kote-Jarai Z, Easton DF,. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45 (4): 385-91 91e1-2. PubMed PMID 23535732.
2. Goh CL, Schumacher FR, Easton D, Muir K, Henderson B, Kote-Jarai Z, Eeles RA,. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 2012; 271 (4): 353-365. PubMed PMID: 22308973. Epub 2012/02/09. eng
3. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF Jr, Thomas G, Hunter DJ, Dean M, Chanock SJ,. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 2009; 106 (19): 7933-7938. PubMed PMID: 19383797. Pubmed Central PMCID 2671324.
4. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dork T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schurmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA, Consortium P, Eeles RA,. Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008; 17 (8): 2052-2061. PubMed PMID: 18708398. Pubmed Central PMCID 2776652.
5. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ,. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40 (3): 310-315. PubMed PMID: 18264096. eng.
6. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF,. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40 (3): 316-321. PubMed PMID: 18264097. eng.
7. Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, Ingles SA, Stern MC, Corral R, Joshi AD, Xu J, Giri VN, Rybicki B, Neslund-Dudas C, Kibel AS, Thompson IM, Leach RJ, Ostrander EA, Stanford JL, Witte J, Casey G, Eeles R, Hsing AW, Chanock S, Hu JJ, John EM, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck TR,. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 2011; 20 (1): 23-32. PubMed PMID: 21071540. Pubmed Central PMCID 3110616.
8. Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Adolfsson J, Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB, Gronberg H, Xu J,. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009; 18 (7): 1368-1375. PubMed PMID: 19153072. eng.
9. Camp NJ, Farnham JM, Wong J, Christensen GB, Thomas A, Cannon-Albright LA,. Replication of the 10q11 and Xp11 prostate cancer risk variants: Results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev 2009; 18 (4): 1290-1294. PubMed PMID: 19336566. Pubmed Central PMCID 2697376.
10. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, Benediktsdottir KR, Magnusdottir DN, Orlygsdottir G, Jakobsdottir M, Stacey SN, Sigurdsson A, Wahlfors T, Tammela T, Breyer JP, McReynolds KM, Bradley KM, Saez B, Godino J, Navarrete S, Fuertes F, Murillo L, Polo E, Aben KK, van Oort IM, Suarez BK, Helfand BT, Kan D, Zanon C, Frigge ML, Kristjansson K, Gulcher JR, Einarsson GV, Jonsson E, Catalona WJ, Mayordomo JI, Kiemeney LA, Smith JR, Schleutker J, Barkardottir RB, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K,. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41 (10): 1122-1126. PubMed PMID: 19767754. eng.
11. Waters KM, Le Marchand L, Kolonel LN, Monroe KR, Stram DO, Henderson BE, Haiman CA,. Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. Cancer Epidemiol Biomarkers Prev 2009; 18 (4): 1285-1289. PubMed PMID: 19318432. Pubmed Central PMCID 2917607.
12. Wiklund F, Zheng SL, Sun J, Adami HO, Lilja H, Hsu FC, Stattin P, Adolfsson J, Cramer SD, Duggan D, Carpten JD, Chang BL, Isaacs WB, Gronberg H, Xu J,. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate 2009; 69 (4): 419-427. PubMed PMID: 19116992. eng.
13. Xu B, Wang J, Tong N, Mi Y, Min Z, Tao J, Li P, Cheng G, Li J, Wang M, Tang J, Song N, Zhang Z, Zhang W, Wu H, Hua L, Feng N,. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression. Prostate 2010; 70 (10): 1146-1152. PubMed PMID 20333697.
14. Xu Z, Bensen JT, Smith GJ, Mohler JL, Taylor JA,. GWAS SNP replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate 2011; 71 (8): 881-891. PubMed PMID: 21456070. Pubmed Central PMCID 3403828.
15. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML,. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 2010; 6 (11): e1001204. PubMed PMID: 21085629. Pubmed Central PMCID 2978684.
16. FitzGerald LM, Zhang X, Kolb S, Kwon EM, Liew YC, Hurtado-Coll A, Knudsen BS, Ostrander EA, Stanford JL,. Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat 2012; 34 (1): 149-156. PubMed PMID: 22887727. eng.
17. Xu X, Valtonen-Andre C, Savblom C, Hallden C, Lilja H, Klein RJ,. Polymorphisms at the microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels. Cancer Epidemiol Biomarkers Prev 2010; 19 (8): 2035-2042. PubMed PMID: 20696662. eng.
18. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, Bjornsdottir US, Eyjolfsson GI, Navarrete S, Fuertes F, Garcia-Prats MD, Polo E, Checherita IA, Jinga M, Badea P, Aben KK, Schalken JA, van Oort IM, Sweep FC, Helfand BT, Davis M, Donovan JL, Hamdy FC, Kristjansson K, Gulcher JR, Masson G, Kong A, Catalona WJ, Mayordomo JI, Geirsson G, Einarsson GV, Barkardottir RB, Jonsson E, Jinga V, Mates D, Kiemeney LA, Neal DE, Thorsteinsdottir U, Rafnar T, Stefansson K,. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010; 2 (62): 62ra-92. PubMed PMID: 21160077. eng.
19. Siegel R, Naishadham D, Jemal A,. Cancer statistics 2012 CA Cancer J Clin 2012; 62 (1): 10-29. PubMed PMID: 22237781. eng.
20. Lilja H, Abrahamsson PA,. Three predominant proteins secreted by the human prostate gland. Prostate 1988; 12 (1): 29-38. PubMed PMID: 3347596. eng.
21. Seidah NG, Arbatti NJ, Rochemont J, Sheth AR, Chretien M,. Complete amino acid sequence of human seminal plasma beta-inhibin. Prediction of post Gln-Arg cleavage as a maturation site. FEBS Lett 1984; 175 (2): 349-355. PubMed PMID: 6434350. Epub 1984/10/01. eng
22. Kohan S, Froysa B, Cederlund E, Fairwell T, Lerner R, Johansson J, Khan S, Ritzen M, Jornvall H, Cekan S, Diczfalusy E,. Peptides of postulated inhibin activity. Lack of in vitro inhibin activity of a 94-residue peptide isolated from human seminal plasma, and of a synthetic replicate of its C-terminal 28-residue segment. FEBS Lett 1986; 199 (2): 242-248. PubMed PMID: 3084296. Epub 1986/04/21. eng
23. Gordon WL, Liu WK, Akiyama K, Tsuda R, Hara M, Schmid K, Ward DN,. Beta-microseminoprotein (beta-MSP) is not an inhibin. Biol Reprod 1987; 36 (4): 829-835. PubMed PMID: 3109514. Epub 1987/05/01. eng
24. Dube JY, Frenette G, Paquin R, Chapdelaine P, Tremblay J, Tremblay RR, Lazure C, Seidah N, Chretien M,. Isolation from human seminal plasma of an abundant 16-kDa protein originating from the prostate, its identification with a 94-residue peptide originally described as beta-inhibin. J Androl 1987; 8 (3): 182-189. PubMed PMID: 3610813. Epub 1987/05/01. eng
25. Akiyama K, Yoshioka Y, Schmid K, Offner GD, Troxler RF, Tsuda R, Hara M,. The amino acid sequence of human beta-microseminoprotein. Biochim Biophys Acta 1985; 829 (2): 288-294. PubMed PMID: 3995056. Epub 1985/06/10. eng
26. Anahi Franchi N, Avendano C, Molina RI, Tissera AD, Maldonado CA, Oehninger S, Coronel CE,. Beta-microseminoprotein in human spermatozoa and its potential role in male fertility. Reproduction 2008; 136 (2): 157-166. PubMed PMID 18469041.
27. Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman GJ, Evans DG, Blanco I, Mercer C, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Kirk J, Lilja H, Easton D, Cooper C, Eeles R, Neal DE,. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS ONE 2010; 5 (10): e13363. PubMed PMID: 20967219. eng
28. Garde S, Sheth A, Porter AT, Pienta KJ,. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate 1993; 22 (3): 225-233. PubMed PMID 8488155.
29. Hagerwall AME, Rydengard V, Fernlund P, Morgelin M, Baumgarten M, Cole AM, Malmsten M, Kragelund BB, Sorensen OE,. Beta-microseminoprotein endows post coital seminal plasma with potent candidacidal activity by a calcium- and pH-dependent mechanism. PLoS Pathog 2012; 8 (4): e1002625. PubMed PMID: 22496651. eng
30. Lazure C, Villemure M, Gauthier D, Naude RJ, Mbikay M,. Characterization of ostrich (Struthio camelus) beta-microseminoprotein (MSP): Identification of homologous sequences in EST databases and analysis of their evolution during speciation. Protein Sci 2001; 10 (11): 2207-2218. PubMed PMID: 11604528. Pubmed Central PMCID: 2374068. Epub 2001/10/18. eng
31. Lokeshwar BL, Block NL,. Isolation of a prostate carcinoma cell proliferation-inhibiting factor from human seminal plasma and its similarity to transforming growth factor beta. Cancer Res 1992; 52 (20): 5821-5825. PubMed PMID: 1394210. Epub 1992/10/15. eng
32. Lokeshwar BL, Hurkadli KS, Sheth AR, Block NL,. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the dunning R3327G rat tumor. Cancer Res 1993; 53 (20): 4855-4859. PubMed PMID: 8402673. eng.
33. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, Tang DG,. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999; 38 (2): 118-125. PubMed PMID: 9973097. eng.
34. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA,. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003; 63 (9): 2072-2078. PubMed PMID: 12727822. eng.
35. Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA,. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy- associated hypercalcemia. Cancer Res 2004; 64 (15): 5370-5377. PubMed PMID: 15289344. eng.
36. Cadieux PA, Mikolajczak SA, Reeves J, Strathdee C, Reid G, Panchal CJ, Clarke MW,. Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro. Cancer Invest 2006; 24 (3): 246-255. PubMed PMID 16809150.
37. Pathak BR, Breed AA, Nakhawa VH, Jagtap DD, Mahale SD,. Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific. Asian J Androl 2010; 12 (5): 677-689. PubMed PMID: 20676114. Epub 2010/08/03. eng
38. Garde S, Fraser JE, Nematpoor N, Pollex R, Morin C, Forte A, Rabbani S, Panchal C, Gupta MB,. Cloning, expression, purification and functional characterization of recombinant human PSP94. Protein Expr Purif 2007; 54 (2): 193-203. PubMed PMID: 17468008. Epub 2007/05/01. eng
39. Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Annabi B,. A prostate secretory protein 94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis. Int J Cancer 2006; 118 (9): 2350-2358. PubMed PMID: 16331603. eng.
40. Hyakutake H, Sakai H, Yogi Y, Tsuda R, Minami Y, Yushita Y, Kanetake H, Nakazono I, Saito Y,. Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 1993; 22 (4): 347-355. PubMed PMID: 8497429. eng.
41. Tsurusaki T, Koji T, Sakai H, Kanetake H, Nakane PK, Saito Y,. Cellular expression of beta-microseminoprotein (β-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998; 35 (2): 109-116.
42. Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW, Saito Y,. Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 1999; 38 (4): 278-284. PubMed PMID: 10075007. eng.
43. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT,. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007; 13 (14): 4130-4138. PubMed PMID: 17634540. Pubmed Central PMCID 2660867.
44. Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL, Moussa M,. PSP94 expression after androgen deprivation therapy: A comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 2000; 164 (5): 1819-1824.
45. Girvan AR, Chang P, van Huizen I, Moussa M, Xuan JW, Stitt L, Chin JL, Yamasaki Y, Izawa JI,. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 2005; 65 (4): 719-723. PubMed PMID 15833515.
46. Porter AT, Ben-Josef E, editors. Humoral mechanisms in prostate cancer: A role for FSH. Urol Oncol 2001; 6 (4): 131-138.
47. Rinckleb AE, Surowy HM, Luedeke M, Varga D, Schrader M, Hoegel J, Vogel W, Maier C,. The prostate cancer risk locus at 10q11 is associated with DNA repair capacity. DNA Repair 2012; 11 (8): 693-701.
48. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE,. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010; 70 (3): 333-340. PubMed PMID 19790236.
49. Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Beliveau R,. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun 2006; 346 (1): 358-366. PubMed PMID: 16759641. Epub 2006/06/09. eng
50. Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Beliveau R,. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: Implication in tumor metastasis. Clin Exp Metastasis 2005; 22 (5): 429-439. PubMed PMID: 16283486. eng.
51. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL,. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62 (15): 4499-4506.
52. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66 (5): 2815-2825.
53. Vanaja DK, Cheville JC, Iturria SJ, Young CY,. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63 (14): 3877-3882. PubMed PMID: 12873976. Epub 2003/07/23. eng
54. Clapham DE,. Calcium signaling. Cell 2007; 131 (6): 1047-1058. PubMed PMID: 18083096. Epub 2007/12/18. eng
55. Ito Y, Tsuda R, Kimura H,. Ultrastructural localizations of beta-microseminoprotein, a prostate-specific antigen, in human prostate and sperm: Comparison with gamma-seminoprotein, another prostate-specific antigen. J Lab Clin Med 1989; 114 (3): 272-277. PubMed PMID: 2475560. eng.
56. Doctor VM, Sheth AR, Simha MM, Arbatti NJ, Aaveri JP, Sheth NA,. Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: Comparison of its distribution in normal, benign and malignant prostates. Br J Cancer 1986; 53 (4): 547-554. PubMed PMID: 2423106. eng.
57. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7 (4): 256-269. PubMed PMID: 17384581. eng.
58. Kohnen PW, Drach GW,. Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urol 1979; 121 (6): 755-760. PubMed PMID: 88527. Epub 1979/06/01. eng
59. Bennett B, Culberson D, Petty C, Gardner W,. Histopathology of prostatitis. J Urol 1990; 143: 265A.
60. Blumenfeld W, Tucci S, Narayan P,. Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am J Surg Pathol 1992; 16 (10): 975-981. PubMed PMID: 1415905. Epub 1992/10/01. eng
61. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID,. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001; 87 (9): 797-805. PubMed PMID: 11412216. Epub 2001/06/20. eng
62. Bernoulli J, Yatkin E, Laakso A, Anttinen M, Bosland M, Vega K, Kallajoki M, Santti R, Pylkkanen L,. Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. Prostate 2008; 68 (7): 728-739. PubMed PMID 18302197.
63. Sfanos KS, De Marzo AM,. Prostate cancer and inflammation: The evidence. Histopathology 2012; 60 (1): 199-215. PubMed PMID 22212087.
64. Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA,. Chronic inflammation in benign prostate tissue is associated with higher-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Submitted.
65. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP,. Evaluation of prostatitis in autopsied prostates-Is chronic inflammation more associated with benign prostatic hyperplasia or cancer ? J Urol 2008; 179 (5): 1736-1740. PubMed PMID: 18343414. Pubmed Central PMCID 2661538.
66. Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N,. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999; 54 (3): 467-472. PubMed PMID 10475356.
67. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R,. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005; 25 (6C): 4435-4438. PubMed PMID 16334122.
68. Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR,. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20 (10): 2280-2287. PubMed PMID: 21953116. Pubmed Central PMCID 3671592.
69. Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, Nagahara A, Aozasa K, Tsujimura A,. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 2011; 107 (12): 1918-1922. PubMed PMID 21044246.
70. Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, Tsujimura A, Nakayama M, Aozasa K, Okuyama A,. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007; 97 (7): 952-956. PubMed PMID: 17848955. Pubmed Central PMCID 2360404.
71. Vesalainen S, Lipponen P, Talja M, Syrjanen K,. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30A (12): 1797-1803. PubMed PMID 7880609.
72. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC,. Reduced infiltration of tumor-associated macrophages in human prostate cancer: Association with cancer progression. Cancer Res 2000; 60 (20): 5857-5861. PubMed PMID 11059783.
73. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W,. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183 (5): 1792-1796. PubMed PMID: 20299055. Epub 2010/03/20. eng
74. Dennis LK, Dawson DV,. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13 (1): 72-79. PubMed PMID 11805589.
75. Taylor ML, Mainous AG III, Wells BJ,. Prostate cancer and sexually transmitted diseases: A meta-analysis. Family Med 2005; 37 (7): 506-512. PubMed PMID 15988645.
76. Sutcliffe S,. Sexually transmitted infections and risk of prostate cancer: Review of historical and emerging hypotheses. Future Oncol 2010; 6 (8): 1289-1311. PubMed PMID 20799875.
77. Hrbacek J, Urban M, Hamsikova E, Tachezy R, Heracek J,. Thirty years of research on infection and prostate cancer: No conclusive evidence for link. A systematic review. Urol Oncol 2012; 31 (7): 951-965. PubMed PMID 22459691.
78. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB,. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 2008; 68 (3): 306-320. PubMed PMID 18163428.
79. el-Demiry MI, Hargreave TB, Busuttil A, James K, Ritchie AW, Chisholm GD,. Lymphocyte sub-populations in the male genital tract. Br J Urol 1985; 57 (6): 769-774. PubMed PMID: 3910154. Epub 1985/12/01. eng
80. Bostwick DG, de la Roza G, Dundore P, Corica FA, Iczkowski KA,. Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 2003; 55 (3): 187-193. PubMed PMID: 12692784. Epub 2003/04/15. eng
81. McClinton S, Miller ID, Eremin O,. An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic disease. Br J Cancer 1990; 61 (3): 400-403. PubMed PMID: 1691655. Pubmed Central PMCID: 1971287. Epub 1990/03/01. eng
82. Bergh J, Marklund I, Gustavsson C, Wiklund F, Gronberg H, Allard A, Alexeyev O, Elgh F,. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer 2007; 96 (1): 137-139. PubMed PMID: 17117176. eng.
83. Wise GJ, Shteynshlyuger A,. How to diagnose and treat fungal infections in chronic prostatitis. Curr Urol Rep 2006; 7 (4): 320-328. PubMed PMID: 16930504. eng.
84. De la Rosette J, Hubregtse M, Meuleman E, Stolk-Engelaar M, Debruyne F,. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993; 41 (4): 301-307.
85. Didier ES, Weiss LM,. Microsporidiosis: Not just in AIDS patients. Curr Opin Infect Dis 2011; 24 (5): 490.
86. Weber R, Bryan RT, Schwartz DA, Owen RL,. Human microsporidial infections. Clin Microbiol Rev 1994; 7 (4): 426.
87. Sak B, Kváč M, Kučerová Z, Květoňová D, Saková K,. Latent microsporidial infection in immunocompetent individuals-A longitudinal study. PLoS Negl Trop Dis 2011; 5 (5): e1162.
88. Birthistle K, Moore P,. Microsporidia: A new sexually transmissable cause of urethritis Microsporidia are worldwide ubiquitous intra. Genitourin Med 1996; 72: 445-452.
89. Ghosh K, Weiss LM,. Molecular diagnostic tests for microsporidia. Interdiscip Perspect Infect Dis 2009; 2009: 926521. PubMed PMID: 19657457. Pubmed Central PMCID: 2719812. Epub 2009/08/07. eng.
90. Strickler HD, Goedert JJ,. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001; 23 (1): 144-151. PubMed PMID 11588840.
91. Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A, Gillevet PM,. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog 2010; 6 (1): e1000713.
92. Lipkin WI,. Microbe hunting. Microbiol Mol Biol Rev 2010; 74 (3): 363-377.
93. Kostic AD, Ojesina AI, Pedamallu CS, Jung J, Verhaak RG, Getz G, Meyerson M,. PathSeq: Software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol 2011; 29 (5): 393-396. PubMed PMID: 21552235. Pubmed Central PMCID: 3523678. Epub 2011/05/10. eng
94. Stott-Miller M, Wright JL, Stanford JL,. MSMB gene variant alters the association between prostate cancer and number of sexual partners. Prostate 2013; 73 (16): 1803-1809.